Harrow Launches Next-Generation Compounded Atropine Formulations

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “Our mission has always been to help our eyecare professionals address their